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Abstract: Ghrelin, a peptide predominantly produced in the stomach exhibits numerous physiological functions, including stimulation of 
growth hormone release, food intake and gastric empting, and regulation of energy expenditure. This peptide exhibits also some 
protective and healing-promoting effects. This review summarizes the recent findings concerning animal and human data showing 
protective and therapeutic effects of ghrelin in the gut. 
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DISCOVERY OF GHRELIN 
Ghrelin has been primary isolated by Kojima et al. from the 
human and rat stomach [1], and the stomach is a main source of 
circulating ghrelin [2]. Ghrelin is an endogenous ligand for the 
growth hormone secretagogue receptor 1a (GHS-R) and acting on 
the anterior pituitary, ghrelin strongly and dose-dependently 
stimulates growth hormone release [1]. The sequence of events 
leading to the discovery of ghrelin was untypical. The discovery of 
this peptide has been preceded by the synthesis of its peptidyl and 
non-peptidyl analogs, called growth hormone secretagogues [3], 
and discovery [4], and cloning of GHS-R [5].  
GHRELIN AND ITS RECEPTORS 
Human ghrelin gene has been mapped to chromosome 3p26-25 
[6]. Ghrelin is initially synthesized as preproghrelin composed of 
117 amino acid residues, which are further processed to acyl 
ghrelin, des-acyl ghrelin and obestatin [7]. Circulating ghrelin 
exists mainly as a 28 amino acid peptide in two major forms, as 
acyl and des-acyl ghrelin [8]. Acyl ghrelin, which present in serum 
in far smaller quantities than des-acyl ghrelin, is recognized as an 
active form of this peptide because the acylation is necessary to the 
binding ghrelin with GHS-R1a. Ghrelin is the one and only peptide 
currently known to be octanoylated [1]. Before extracellular 
secretion, ghrelin undergoes posttraslatory estrification in which 
hydroxyl group of serine-3 residue is acylated by n-octanoic acid 
(8-carbon fatty acid). In addition, there also some naturally 
occurring variants of acyl ghrelin. Hosoda et al. [9] have found that 
serine-3 residue apart from acylation by n-octanoic acid may be 
also decanoylated (C10:0), and possibly decenoylated (C10:1). Des-
Gln14-ghrelin is another endogenous analog of ghrelin and this 
peptide is a result of alternative splicing of ghrelin gene undergoes 
the same process of acylation of serine-3 residue and possesses the 
same hormonal activity as a 28-residue ghrelin [3; 10]. 
The enzyme that catalyzes the acylation of ghrelin has been 
discovered in 2008 and called ghrelin o-acyltransferase (GOAT) 
[11]. GOAT belongs to a family of hydrophobic membrane-bound 
acyltransferases and mRNA for GOAT is mainly restricted to the 
stomach, the major source of endogenous ghrelin [11]. Study in 
vitro has shown that the GOAT-containing membranes transfer the 
octanoyl group from octanoyl CoA to recombinant proghrelin, as 
well as to a pentapeptide containing only the N-terminal five amino 
acids of proghrelin [12]. Moreover, GOAT activity can be inhibited 
by an octanoylated ghrelin pentapeptide, suggesting that GOAT is 
subjected to end-product inhibition [12]. 
Des-acyl ghrelin does not bind to GHS-R1a and is deprived of 
growth hormone release activity. For this reason, des-acyl ghrelin 
was primary recognized as inactive form of ghrelin. However, 
several studies have shown that des-acyl ghrelin may exhibit some 
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non-endocrinological actions including participation in the 
regulation of food intake, gut motility, adipogenesis, insulin 
secretion and resistance [13], as well as exerts cardiovascular [14; 
15] and anti-proliferative effects [16]. These biological effects of 
des-acyl ghrelin are speculated to be a result of its binding to a 
novel, as yet unidentified receptor different from the classic ghrelin 
receptor, GHS-R1a [15]. 
Ghrelin is predominantly produced in the gastric oxyntic 
mucosa [1, 2, 17], but its presence was also detected in the most 
tissues, including among others the small and large bowel, 
pancreas, myocardium, pituitary or hypothalamus [1, 17, 18]. Total 
gastrectomy reduces serum level of ghrelin by 65% [2]. In the 
stomach, ghrelin is produced by the X/A-like cells. These cells 
represent about one fifth of all gastric endocrine cells in oxyntic 
mucosa [17]. X/A cells are small and round-shaped without contact 
with a stomach lumen (close-type cells). In the small and large 
bowel, there are two types of ghrelin-secreting cells. closed-type 
cells with triangular or elongated shapes, and opened-types cells 
with their apical cytoplasmic process contacting to the intestinal 
lumen [19]. The number of the opened-type cells gradually 
increases in the direction from the stomach to the lower 
gastrointestinal tract [20].  
The presence of ghrelin-immunoreactive cells in the gut is age-
dependent. In the stomach, ghrelin-positive cells are present starting 
from 18
th
 day of the pregnancy and the number of these cells 
increases in an age-dependent manner from the neonatal to adult 
stage [21]. In contrast to that, in fetal period of life, pancreatic 
ghrelin cells are relatively numerous [22]. Later, the number of 
ghrelin-immunoreactive cells is reduced and these cells are 
localized at the periphery of human and rat pancreatic islets [22; 
23]. 
Fasting plasma level of ghrelin is negatively correlated with 
body mass index in adult humans [24]. Obesity, food intake and 
glucose administration decrease plasma ghrelin concentration [2, 
24, 25]; whereas fasting or anorexia nervosa increase plasma level 
of this peptide [2, 24]. 
The human GHS-R gene is located on human chromosome 3, at 
the position 26-27 and consists of two exons; the first exon encodes 
transmembrane domains 1-5, and the second exon encodes 
transmembrane domains 6 and 7 [26]. Two types of ghrelin receptor 
cDNAs have been identified, GHS-R cDNA 1a and, GHS-R cDNA 
1b. GHS-R cDNA type 1a encodes functional receptor for ghrelin 
[26]. GHS-R1a is a typical G protein-coupled receptor (GPCR) 
with seven transmembrane domains and molecular mass of 41 kDa 
[3]. Binding GHS or ghrelin to GHS-R1a activates phospholipase C 
to generate IP3 and diacylglycerol, leading to an increase in 
intracellular Ca
2+
. Activation of GHS-R1a also causes an inhibition 
of K
+ 
ion channels, leading to entry of Ca
2+
 through voltage-
operating L-type channels [3]. GHS-R cDNA type 1b is a result of 
alternative splicing mechanism [26]. It is derived from only the first 
exon and encodes only five of the seven predicted transmembrane 
domains. Although mRNA for GHS-R1b does not seem to end in 
the transcription of the protein, expression of this mRNA is 
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widespread in many organs, but its significance remains to be 
determined [3, 18]. 
GHS-R1a mRNA is predominantly expressed in the pituitary 
and hypothalamus; however their presence has also been shown in 
other central and peripheral tissues, but at much lower levels [18, 
26]. GHS-R expression is highly sensitive to a level of growth 
hormone. In growth hormone-deficient dw/dw dwarf rats, 
expression of mRNA for GHS-R is increased, and administration of 
growth hormone reduced expression of this receptor in these rats 
[27]. Expression of GHS-R is also related to growth hormone-
releasing hormone (GH-RH) and growth hormone secreatogogues 
(GHSs). Intravenous treatment with GH-RH increases expression of 
GHS-R mRNA in the pituitary and this effect is independent of 
somatostatin [28]. On the other hand, administration of GHSs 
down-regulates the GHS-R mRNA expression [28]. 
MAIN BIOLOGICAL EFFECTS OF GHRELIN 
The main physiological function of ghrelin found by Kojima 
was strong and dose dependent stimulation of growth hormone 
release from the anterior pituitary [1]. This effect has been observed 
both in vivo and in vitro studies indicating direct action of ghrelin 
on somatotroph cells. However, the involvement of the 
hypothalamus in ghrelin-mediated release of growth hormone has 
been also found. GH-RH neurons express GHS-R [29] and systemic 
administration of GHS increases c-fos expression in GH-RH-
containing neurons [30]. Moreover, systemic treatment with GHS 
causes a 50% increase in GH-RH pulse frequency in portal blood of 
the pituitary [31]. In agreement with these findings is observation 
that release of growth hormone in patients with organic lesion in the 
hypothalamic area and treated with ghrelin is more than 35-fold 
lower than in control group [32]. There are also data showing the 
involvement of vagal nerve in the ghrelin-induced secretion of 
growth hormone. Vagotomy, as well as blockade of the gastric 
vagal nerves by capsaicin abolish the ghrelin-induced GH secretion 
and activation of GH-RH-producing neurons [33]. Activity of 
ghrelin also includes stimulatory effect on the release of 
adrenocortocotropic hormone (ACTH), corticosterone and prolactin 
[34] 
Beside a release of growth hormone, administration of ghrelin 
generates a positive energy balance. Peripheral or intracerebro-
ventricular treatment with ghrelin increases food intake and fat 
deposition in rats [35]. Also human studies indicate that intravenous 
administration of ghrelin stimulates food intake from a free-choice 
buffet [36]. The orexigenic effect of ghrelin is mediated by 
activation of hypothalamic neurons expressing neuropeptide Y, 
agouti-related protein (AgRP) [37] and orexin [38], as well as by 
inhibition of hypothalamic proopiomelanocortin (POMC) neurons 
[39]. There are also papers showing that orexigenic effect of ghrelin 
involves the influence of this peptide on vagal nerve activity. 
Satiety peptides such as cholecystokinin, increase gastric vagal 
afferent discharge. In contrast to that ghrelin decreases activity of 
afferent vagal nerves [40]. Apart from an increase in appetite, the 
ghrelin-induced positive energy balance involves a decrease in 
energy expenditure and a reduction in cellular fat oxidation [41]. 
Ghrelin affects the development and maturation of digestive 
tract organs and this effect is age-dependent. In young suckling rats, 
administration of ghrelin reduces gastric and pancreatic growth; 
whereas in young adult rats, treatment with ghrelin stimulates 
gastric and pancreatic growth and increases pancreatic activity of 
amylase [42-44]. 
Ghrelin stimulates gastric motility [45] and gastric emptying 
[46]. Influence of ghrelin on gastric acid secretion is unclear. 
Some studies with anesthetized rats have shown that intravenous 
[45] or intracerebroventricular administration of ghrelin [47] 
stimulates gastric acid secretion. Another study with conscious rats 
has shown that central administration of ghrelin inhibits gastric acid 
secretion [48]; whereas a study performed in rats with chronic 
gastric fistulas or ligation of pylorus suggests that ghrelin does not 
affect secretion of acid in the stomach [46]. 
The role of ghrelin in endocrine and exocrine pancreatic 
secretion is likewise under debate. Some studies have reported that 
ghrelin inhibits insulin secretion in the isolated rat pancreas 
perfused in situ [49], in anesthetized mice and isolated mouse islets 
[50] and in humans [51]. In contrast to that, other studies have 
shown that ghrelin stimulates insulin secretion in isolated rat 
pancreatic islets [23] and in anesthetized rats [52]. These 
discrepancies may be a result of species differences and/or 
experimental conditions. Effect of ghrelin on pancreatic exocrine 
secretion seems to be more established. Experiments performed by 
Zhang et al. [53] have shown that intravenous administration of 
ghrelin inhibits the cholecystokinin- and 2-deoxy-D-glucose-
stimulated pancreatic exocrine secretion in anesthetized rats, as well 
as that ghrelin inhibits the potassium-stimulated amylase secretion 
from isolated pancreatic lobules. These observations are supported 
by data obtained by Kapica et al. [54]. They have studied the 
influence of pentaghrelin, an active fragment of ghrelin, on 
pancreatic juice secretion in anaesthetized rats. Intravenous 
administration of pentaghrelin has dose-dependently reduced the 
secretion of pancreatic juice and pancreatic protein output in basal 
conditions and after stimulation by cholecystokinin. Administration 
of pentaghrelin has failed to affect pancreatic secretion in rats 
subjected to vagotomy, capsaicin deactivation of afferent nerves or 
pretreatment with CCK1 receptor antagonist [54]. On the other 
hand, intracerebroventricular administration of ghrelin has been 
reported to increase pancreatic exocrine secretion via the vagal 
nerves in conscious rats [55]. 
Previous studies have shown that treatment with ghrelin 
protects the heart [56], kidney [57] and brain [58] against ischemic 
injury and attenuates sepsis-induced lung injury and mortality [59]. 
Animal studies have shown that administration of hexarelin, a 
synthetic GHS, as well as ghrelin reduces infarct size in isolated 
working rat hearts subjected to 30 minutes of ischemia followed by 
120 minutes of reperfusion [56]. This effect has been partly 
abolished by the protein kinase C inhibitor [56]. These observations 
suggest that cardioprotective effect of GHS is independent of 
growth hormone secretion. This concept is additional supported by 
findings that GHSs exhibit cardioprotective effect in hypophy-
sectomized rats [60] and ghrelin, and even des-acyl ghrelin inhibit 
apoptosis of cultured primary adult and H9c2 cardiomyocytes [61]. 
Human studies have shown that chronic administration of ghrelin in 
patients with chronic heart failure leads to increase in left 
ventricular ejection fraction and ventricular mass, as well as to 
decrease in left ventricular end-systolic volume [62]. These effects 
have been associated with the ghrelin-induced increase in peak 
workload and peak oxygen consumption during exercise, muscle 
strength, and lean body mass. Moreover, long-lasting treatment 
with ghrelin has significantly decreased plasma concentration of 
norepinephrine in patients with chronic heart failure [62]. This last 
observation is in agreement with finding that administration of 
ghrelin decreases systolic and diastolic blood pressure in lean and 
overweight or obese subjects in resting conditions, as well as 
reduces the stress-induced increase in blood pressure, heart rate and 
muscle sympathetic nervous system activity in these groups of 
humans [63]. 
PROTECTIVE EFFECTS OF GHRELIN IN THE GUT 
Protective effect of ghrelin administration has been found in 
different organs of the gut such as the stomach, pancreas, intestine 
and liver. 
Gastroprotective Effect of Ghrelin 
Pretreatment with ghrelin protects gastric mucosa against 
damage evoked by ethanol, stress, ischemia-reperfusion, 
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alendronate or HCl. In 2003, Sibilia et al. have reported that 
intracerebroventricular treatment with ghrelin causes dose-
dependent reduction in ethanol-induced gastric ulcers in conscious 
rats [64]. Protective effect of ghrelin given subcutaneously was 
much weaker, only ulcer depth has been significantly reduced. 
Moreover, they have found that inhibition of NO synthesis and 
capsaicin-induced sensory nerves denervation, but not vagotomy 
prevents the gastroprotective effect of ghrelin given centrally. For 
this reason Sibilia et al. have concluded that gastroprotective effect 
of ghrelin is mediated by endogenous NO release and requires the 
integrity of sensory nerve fibers [64]. In partial harmony with these 
findings are observation performed in rats by Konturek et al. [65]. 
They have found that peripheral intraperitoneal pretreatment with 
ghrelin reduces dose-dependently acute gastric lesions, improves 
gastric mucosal blood flow and reverses the ethanol-induced 
increase in gastric mucosal expression of tumor necrosis factor-. 
On the other hand, they have also observed that pretreatment with 
indomethacin, which has suppressed the mucosal generation of 
prostaglandin E2 by about 85%, has augmented the ethanol-induced 
gastric lesions and eliminated the ghrelin-induced protection of 
mucosa against ethanol. Later, the role of prostaglandin E2 in the 
ghrelin-induced gastroprotection against gastric injury evoked by 
ethanol has been also raised by other authors [66]. 
Pretreatment with ghrelin has been also found to protect gastric 
mucosa against injury evoked by water immersion and restraint 
stress (WRS) [67]. Intraperitoneal administration of exogenous 
ghrelin has been found to increase gastric acid secretion and 
attenuate gastric lesions induced by WRS. These effects were 
accompanied by a significant rise in plasma ghrelin level, gastric 
mucosal blood flow and luminal NO concentrations. The ghrelin-
induced protection has been attenuated by suppression of 
cyclooxygenases, deactivation of afferent nerves and inhibition of 
nitric oxide synthase (NOS) [67]. Brzozowski et al. has also found 
that protective effect of ghrelin given intraperitoneally is abolished 
by vagotomy [67]. This last effect is in contrast to results obtained 
by Sibilia at al. [64]. These discrepancies seem to be a result of 
different routes of ghrelin administration and models of mucosal 
injury. In study performed by Sibilia et al., ghrelin has been 
administered centrally and gastric ulcers have been induced by 
intragastric application of ethanol. 
Ghrelin has been also found to protect rat gastric mucosa 
against damage evoked by ischemia followed by reperfusion. This 
effect has been observed after ghrelin given intraperitoneally [68-
70] and intracerebroventricularly [70]. Studies performed by 
Konturek et al. [68] have shown that administration of ghrelin 
significantly attenuates the ischemia/reperfusion-induced gastric 
lesions and this effects is associated with an increase in gastric 
mucosal blood flow, a decrease in plasma TNF- and a reduction in 
NF-B activation. As in other model of gastric ulcers, deactivation 
of sensory nerves with capsaicin [68-70], inhibition of cNOS by L-
NNA [68], inhibition of prostaglandin E2 production by blockade of 
cyclooxygenases [69] or vagotomy [70] has significantly attenuated 
the protective activity of ghrelin in ischemia/reperfusion-induced 
gastric ulcers [68]. Moreover, Brzozowski et al. [69] have shown 
that protective effect of ghrelin in this mode of gastric injury has 
been attenuated by pretreatment with d-Lys(3)-GHRP-6, a selective 
antagonist of GHS-R1a. In ischemia/reperfusion-induced gastric 
injury, protective effect of ghrelin seems to be also related to 
reduction in myeloperoxidase activity and mucosal content of 
malonyldialdehyde (MDA), a product of lipid peroxidation [69].  
Sodium alendronate sodium, an amino bisphosphonate, is 
widely used in the treatment of various diseases that are associated 
with bone resorption, such as postmenopausal osteoporosis and 
Paget's disease. Ieri et al. [71] have shown that treatment with 
ghrelin attenuates gastric mucosa damage evoked by alendronate 
and this effect has been associated with a reduction in the 
alendronate-induced increase in serum TNF- concentration, gastric 
MDA content and myeloperoxidase activity. Moreover, treatment 
with ghrelin has been reported to reverse the alendronate-induced 
decrease in gastric mucosa glutathione concentration [71]. They 
have concluded that ghrelin reduces alendronate-induced gastric 
damage and this effect is related to ghrelin’s anti-inflammatory and 
antioxidant properties. Interestingly, Ieri et al. have used ghrelin at 
the dose of 10 ng/kg/day. This dose is 1000 fold lower than doses 
used by other investigators [64-70, 72]. 
Gastroprotective effect of ghrelin has been also tested in gastric 
damage induced by intragastric administration of 0.6 N HCl. Adami 
et al. [72] have found that pretreatment of conscious rats with 
ghrelin administered intraperitoneally at the dose of 40 g/kg 
significantly reduces by 43% gastric lesions evoked by 
concentrated HCl. This effect has been abolished by prior 
intraperitoneal administration of GHS-R1a antagonist, [D-Lys]-
GHRP-6 or by subcutaneous injection of histamine H3 receptor 
antagonist, UCL2138. Neither [D-Lys]-GHRP-6 nor UCL2138 
given without ghrelin has modified HCl-induced gastric damage. 
This observation indicates that gastroprotective effect of ghrelin 
involves the release of histamine, which enhances gastric mucosal 
defense through the activation of histamine H3 receptors [72]. 
Moreover, this observation taken together with gastroprotective 
effects of ghrelin in other models of gastric injury suggest that 
ghrelin-induced protection of the stomach exhibits universal nature 
and is independent of type of noxious agent. 
Protective Effect of Ghrelin Administration in the Intestine 
Wu et al. [73] have investigated the influence of intravenous 
and intracerebroventricular ghrelin administration on the 
ischemia/reperfusion-induced intestinal injury. Rats were exposed 
to gut ischemia by clamping of mesenteric artery for 90 min 
followed by reperfusion for next 2 h. Immediately after removing of 
microvascular clip ghrelin has been administered intravenously 
over a period of 30 min. Intracerebroventricular administration of 
ghrelin has been performed at the beginning of reperfusion. Wu et 
al. have found that intravenous ghrelin administration inhibits pro-
inflammatory cytokine release, reduces neutrophil infiltration in the 
intestine and lungs, ameliorates intestinal barrier dysfunction, 
attenuates intestinal and pulmonary injury, and improves survival of 
rats after gut ischemia/reperfusion-induced injury. Similar 
protective effect has been observed after intracerebroventricular 
administration of ghrelin. Wu et al. have also observed that 
intravenous administration of GHS-R1a antagonist increases the 
ischemia/reperfusion-induced intestinal and pulmonary injury and 
animal mortality [73]. Beneficial effect of intravenous 
administration of ghrelin has been completely eliminated by 
previous vagotomy. Data obtained by Wu et al. indicate that 
administration of ghrelin is able to reduce intestinal and pulmonary 
injury and inflammation in gut ischemia followed by reperfusion. 
Protective Effect of Ghrelin Administration in the Pancreas 
Animal studies have shown that pretreatment with ghrelin 
inhibits the development of cerulein-, ischemia/reperfusion- and 
taurocholate-induced acute pancreatitis. In 2003 we have found that 
intraperitoneal treatment with ghrelin attenuates the development of 
acute pancreatitis evoked by cerulein [74]. Development of acute 
pancreatitis by cerulein leads to pancreatic damage associated with 
an increase in biochemical markers of acute pancreatitis severity. 
Plasma lipase activity and plasma concentration of pro-
inflammatory interleukin-1 are increased; whereas pancreatic 
DNA synthesis, an index of pancreatic cell proliferation is 
decreased. We have observed that administration of ghrelin reduces 
pancreatic inflammatory infiltration and vacuolization of acinar 
cells, and reverses the cerulein-evoked increase in plasma activity 
of lipase and plasma concentration of interleukin-1, as well as 
increases pancreatic DNA synthesis. These findings have suggested 
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that protective effect of ghrelin administration against cerulein-
induced pancreatitis involves the inhibition of inflammatory process 
and the reduction in liberation of pro-inflammatory interleukin-1. 
In 2006 we have shown that administration of ghrelin inhibits 
the development of ischemia/reperfusion-induced acute pancreatitis 
and using pituitary-intact and hypophysectomized rats, we have 
demonstrated the involvement of growth hormone (GH) and 
insulin-like growth factor-1 (IGF-1) in this effect [75]. In pituitary-
intact rats, treatment with ghrelin has attenuated the development of 
ischemia/reperfusion-induced pancreatitis and this effect was 
associated with partial reversion of the pancreatitis-evoked decrease 
in serum concentration of GH and IGF-1. Hypophysectomy has 
eliminated GH from the serum and reduced serum IGF-1 
concentration by 90% and these effects were associated with an 
increased in the severity of ischemia/reperfusion-induced 
pancreatitis. Administration of ghrelin was without any beneficial 
effect in hypophysectomized rats. In contrast, administration of 
IGF-1 in hypophysectomized rats has reduced the severity of acute 
pancreatitis. These observations indicate that protective effect of 
ghrelin against the development of ischemia/reperfusion-induced 
pancreatitis is closely dependent on the release of GH and IGF-1. 
Influence of treatment with ghrelin on the development of 
severe taurocholate-induced pancreatitis has been studied by Zhou 
and Xue [76, 77]. They have found that injection of sodium 
taurocholate into the pancreaticobiliary duct leads to the 
development of morphological signs of pancreatic and hepatic 
damage and this effect is associated with an increase in serum 
amylase activity and serum concentration of TNF-, interleukin-1, 
and interleukin-6. Moreover, they have observed that induction of 
acute pancreatitis by taurocholate increases pancreatic and hepatic 
expression of NF-B p65 [76]. Treatment with ghrelin has been 
found to attenuate the morphological signs of damages in the 
pancreas and liver, and reduce the serum parameters of systemic 
inflammation, and the severity of acute pancreatitis. They have also 
shown that administration of ghrelin reduces pancreatic and hepatic 
expression of nuclear factor (NF) B p65. Zhou and Xue have 
concluded that ghrelin inhibits the development of acute 
pancreatitis induced by sodium taurocholate and this protective 
effect involves inhibition of NF-B expression, leading to blockade 
of inflammatory signal transduction and reduction in the release of 
pro-inflammatory cytokines [76]. 
This finding has been supported and extended by next study 
performed by Zhou and Xue [77]. They have additionally found 
that exogenous ghrelin attenuates the severity of acute lung injury 
induced by the taurocholate-evoked acute pancreatitis. Mechanism 
of this protective effect of ghrelin seems to be the effect of 
reduction in neutrophil sequestration, limitation of proinflammatory 
cytokines release, and inhibition of pulmonary substance P 
expression. 
In the pancreas, ghrelin has been also found to protect 
pancreatic  cells. Granata et al. [78] have investigated the effect of 
acyl ghrelin and des-acyl ghrelin on cell survival of cultured HIT-
T15 pancreatic  cells. They have shown that both acyl and des-
acyl ghrelin equally prevents  cell death induced by serum 
withdrawal. In addition, both peptides inhibit the serum starvation-
induced apoptosis.  
This observation has been extended by next study performed by 
Granata et al. [79]. They have demonstrated that acyl and des-acyl 
ghrelin promotes survival of both  cells and human islets. These 
effects are independent of GHS-R1a, are likely mediated by acyl 
ghrelin/des-acyl ghrelin binding sites, and involve cAMP/PKA, 
ERK1/2, and PI3K/Akt [79]. 
Protective effect of ghrelin on  pancreatic cell has been also 
reported by Wang et al. [80, 81]. Lipotoxicity plays an important 
role in underlying mechanism of type 2 diabetes. Prolonged 
exposure of pancreatic  cells to elevated levels of fatty acid is 
associated with  cell apoptosis. Studies performed by Wang et al. 
have shown that ghrelin promotes cell survival and attenuates the 
palmitate-induced apoptosis in pancreatic  cell line MIN6. 
Exposure of MIN6 cells to ghrelin causes a rapid activation of 
protein kinase B (PKB) and inhibition of c-Jun N-terminal kinase 
(JNK) under lipotoxic state. Furthermore, LY294002, a 
phosphoinositide-3-kinase (PI3K) inhibitor, abolishes the anti-
lipotoxic effect of ghrelin, as well as the ghrelin-induces inhibition 
of JNK, while JNK inhibitor, SP600125 enhances protective effect 
of ghrelin on MIN6 cells. Ghrelin also inhibits the mitochondrial 
pathway of apoptosis and it down-regulates Bax in MIN6 cells. In 
secretion experiment, ghrelin has suppressed insulin release under 
palmitate-incubated state. These findings suggest that ghrelin may 
prevent lipotoxicity-induced apoptosis in MIN6 cells through 
activation of PKB, inhibition of JNK and mitochondrial pathway 
[80]. Wang et al. have also suggested that ghrelin protects 
pancreatic  cells from lipotoxicity by inhibiting the nuclear 
translocation of the transcription regulator FoxO1 [81]. 
Protective Effect of Ghrelin on the Liver 
Clinical studies have suggested that high fasting serum level of 
ghrelin prevents humans against development of gallstone disease 
[82] and nonalcoholic fatty liver disease [83]. Protective effect of 
ghrelin on the liver has been also shown in animal experimental 
studies. Treatment with ghrelin reduces the acetaminophen-induced 
liver injury [84] and the carbon tetrachloride-induced liver injury 
[85]. Cetin et al. have suggested that hepatoprotective effect of 
ghrelin is related to a reduction in oxidative stress [85]. Moreover, 
Arıcı et al. have shown that administration of exogenous ghrelin 
reduces the carbon tetrachloride-induced coagulation disturbances 
in rats [86]. 
THERAPEUTIC EFFECTS OF GHRELIN IN THE GUT 
As shown above, pretreatment with ghrelin inhibits the 
development of damage or inflammation in the stomach, 
duodenum, intestine, pancreas and liver. However, protective effect 
requires administration of ghrelin before exposure to damaging 
factor and therefore has a limited clinical value. Clinically patients 
are usually seen several hours or days after the onset of the disease 
and therapy is usually started after admission to the hospital. For 
this reason, therapeutic effects of ghrelin in the gut are more 
important than protective effects of this peptide. 
Our experimental studies performed on rats have shown that 
treatment with exogenous ghrelin accelerates healing of gastric and 
duodenal ulcers evoked by acetic acid [87]. Chronic ulcers were 
induced in pituitary-intact or hypophysectomized rats. After 
induction of ulcers, rats were treated intraperitoneally twice a day 
with saline, ghrelin or IGF-1 for six or ten days. In animals with 
intact pituitary, treatment with ghrelin increased serum level of GH 
and IGF-1. These effects were accompanied by the increase in 
mucosal cell proliferation, mucosal blood flow and healing rate of 
gastric and duodenal ulcers. After hypophysectomy, the significant 
increase in serum level of endogenous ghrelin was observed, but the 
healing of gastric and duodenal ulcers was delayed. This effect was 
accompanied by a significant decrease in serum concentration of 
endogenous GH and IGF-1, and reduction in mucosal blood flow 
and DNA synthesis. In hypophysectomized rats, administration of 
exogenous ghrelin was without any effect on serum level of GH and 
IGF-1, healing rate of gastroduodenal ulcers or mucosal cell 
proliferation. In contrast to this effect, administration of IGF-1 
increased mucosal cell proliferation, healing rate of gastroduodenal 
ulcers and mucosal blood flow in hypophysectomized rats. These 
findings indicate that treatment with ghrelin accelerates healing of 
chronic gastric and duodenal ulcers and this effect is mediated by 
the release of endogenous GH and IGF-1. 
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Experimental studies have also shown that treatment with 
ghrelin exhibits therapeutic effect in the course of cysteamine-
induced duodenal ulcers [88]. We have found that treatment with 
ghrelin increases healing rate of duodenal ulcers and this effect is 
related, at least in part, to improvement of duodenal mucosal blood 
flow, the increase in mucosal cell proliferation and antioxidant 
defense, as well as to reduction in mucosal oxidative stress and 
inflammatory response [88]. 
Studies performed on rats have also shown that treatment with 
ghrelin after development of cerulein-induced acute pancreatitis 
reduces the severity of this disease and accelerates pancreatic 
recovery [89]. This effect seems to be related to the ghrelin-evoked 
improvement of pancreatic blood flow, reduction in systemic and 
local inflammation and stimulation of pancreatic cell proliferation 
[89]. Moreover studies with hypophysectomized rats have shown 
that therapeutic effect of ghrelin in the course of cerulein-induced 
pancreatitis is indirect and involves the release of endogenous GH 
and IGF-1 [90]. 
Influence of ghrelin administration on experimental and clinical 
colitis is controversial. Gonzalez-Rey et al. have studied therapeutic 
effect of ghrelin in mouse model of colitis [91]. They have found 
that treatment with ghrelin significantly ameliorates the severity of 
the trinitrobenzene sulfonic acid (TNBS)-induced colitis; 
abrogating body weight loss, diarrhea, and inflammation; and 
increasing mouse survival. This therapeutic effect has been 
associated with down-regulation of both inflammatory T helper cell 
1 (Th1)-driven autoimmune response through the regulation of a 
wide spectrum of inflammatory mediators. Moreover, Gonzalez-
Rey et al. have found that this healing effect involves regulatory T 
cells secreting interleukin-10 and transforming growth factor-1. 
Administration of ghrelin has been also shown to attenuate the 
recurrence of colitis after repeated administration of TNBS. Finally, 
Gonzalez-Rey et al. have concluded that treatment with ghrelin 
exhibits anti-inflammatory activity leading to inhibition of large 
bowel inflammatory response and restoration of mucosal immune 
tolerance at multiple levels. Moreover, they have suggested that 
ghrelin administration represents a novel possible therapeutic 
approach for the treatment of Crohn's disease and other Th1-
mediated inflammatory diseases, such as rheumatoid arthritis and 
multiple sclerosis [91]. 
In harmony with these findings are clinical and animal study 
performed by Konturek et al. [92]. The aim of their study was: (a) 
to examine the expression of ghrelin and TNF-alpha mRNA in the 
inflamed colonic mucosa of patients with ulcerative colitis, (b) to 
determine the effect of treatment with exogenous ghrelin on the 
healing of TNBS-induced colitis in rats, and (c) to assess the effects 
of ghrelin treatment on mRNA expression for iNOS and protein 
expression for COX-2 and PPAR in colonic mucosa in intact 
animals and animals with colitis. Clinical part of study has shown 
that patients with ulcerative colitis exhibit a significant upregulation 
of mRNA for ghrelin and TNF- in colonic mucosa as compared to 
that observed in healthy controls. The ratio of expression of ghrelin 
has been found to be well correlated with the grade of colonic 
inflammation and expression of TNF-. Animal part of study has 
shown that intraperitonel treatment ghrelin significantly accelerates 
the healing of TNBS-induced colitis and this effect is accompanied 
by an increase in iNOS mRNA expression and synthesis of COX-2 
in the colonic mucosa. On the other hand, treatment with ghrelin 
has been without effect on synthesis of PPAR in rats with TNBS-
induced colitis. These findings suggests that endogenous and 
exogenous ghrelin protects and accelerates the healing of inflamed 
colonic mucosa and these effects are mediated, at least in part by 
NO and prostaglandins [92]. 
Opposite effects of ghrelin on the course of colitis has been 
found by De Smet et al. [93]. They have induced colitis in wild-
type (ghrelin+/+), ghrelin knockout (ghrelin-/-) and non-inbred 
Swiss mice by adding 3% dextran sodium sulphate (DSS) to 
drinking water for 5 days. After induction of colitis, non-inbred 
Swiss mice have been subsequently divided to two groups, treated 
intaperitoneally with saline or ghrelin. De Smet et al. have reported 
that the colitis-induced body weight loss, histological damage, 
myeloperoxidase activity and interleukin-1 level are attenuated in 
ghrelin(-/-) mice when compared with ghrelin(+/+) mice. 
Moreover, they found that 10 days treatment of non-inbred Swiss 
mice with exogenous ghrelin enhances the severity of colitis, 
promotes inflammatory and increases colonic level of pro-
inflammatory interleukin-1. Authors have concluded that 
endogenous and exogenous ghrelin enhances the colonic 
manifestations of dextran sodium sulphate-induced colitis in mice 
[93].  
Inconsistency between therapeutic effect of ghrelin in colitis 
observed by Gonzalez-Rey et al. [91] and Konturek et al. [92] and 
deleterious effect of ghrelin in the course of this disease reported by 
De Smet et al. [93] may be explained by differences in methods of 
colitis induction. Moreover, study performed by De Smet et al. 
exhibits some methodological inefficiency. It is most likely that 
severity of colitis depends on total dextran sodium sulphate (DSS) 
intake and intake of DSS per body mass unit. Authors have 
declared that there was no difference in total water/DSS intake 
between experimental groups. However initial body mass of 
animals have not been shown and for this reason intake of DDS per 
body mass unit is unknown. 
Very interesting clinical study has been reported by Adachi et 
al. from Osaka [94]. Body weight loss and reduction in serum 
ghrelin level are commonly observed after total gastrectomy. A 
prospective randomized placebo-controlled phase II study has been 
performed to elucidate whether exogenous ghrelin administration 
prevents postoperative body weight loss by improving appetite and 
oral food intake in patients after total gastrectomy due to gastric 
cancer. Patients have been treated intravenously with synthetic 
human ghrelin. This treatment has significantly increased appetite 
and food intake, and lowered body weight loss. Adachi et al. have 
concluded that short-term treatment with synthetic human ghrelin 
safely and effectively reduces postoperative body weight loss and 
improves appetite and food intake in patients after total 
gastrectomy. 
The same medical team has also performed a prospective 
randomized placebo-controlled phase II clinical study to evaluate 
whether administration of exogenous ghrelin can ameliorate the 
postoperative oral food intake and body weight in patient after 
esophagectomy due to esophageal cancer [95]. Authors have found 
that treatment with ghrelin in these patients increases food intake 
and attenuates weight loss. 
Ghrelin stimulates food intake and gastric empting. Moreover, 
animal studies has shown that abdominal surgery induces a rapid 
and long-lasting decrease in plasma acyl ghrelin level associated 
with a decrease in gastric and plasma ghrelin-O-acyltransferase 
(GOAT) protein concentration [96]. For these reasons ghrelin can 
be used in the treatment of functional dyspepsia and postoperative 
ileus. For example, animal studies have shown that administration 
of ghrelin or its analogs improves postoperative [97, 98] and septic 
ileus [99]. These findings encouraged investigators to perform 
clinical studies. Akamizu et al. have shown that repeated 
administration of ghrelin stimulates appetite in patients with 
functional dyspepsia [100]. Synthetic analogs of ghrelin have been 
also found to be effective in the treatment of diabetic gastroparesis 
[101] and postoperative ileus after partial colectomy [102]. 
CONLUSIONS 
Ghrelin, a growth hormone release stimulating peptide exhibits 
numerous effects in the gut suggesting its application in the clinic. 
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Animal studies have shown that ghrelin protects against damage 
different organs in the gut, such as the stomach, pancreas, liver and 
intestine. Experimental studies have also indicated that treatment 
with ghrelin accelerates the recovery in the course of gastric ulcer, 
acute pancreatitis and colitis. Animal and clinical studies have 
shown that ghrelin may be useful in the treatment of dyspepsia, 
postoperative and the septic shock-induced ileus and during 
recovery after total gastrectomy or esophagectomy. Further studies 
are indispensable to check ghrelin dosing, adverse effects and route 
of administration in clinical practice. 
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